Leading biotech companies through the turbulence of the past few years and the uncertainty of the next ones takes not just resilience, but an ability to grapple with the CEO’s paradox, according to Climb Bio CEO Aoife Brennan. This paradox requires preparing for repeated setbacks while planning optimistically, a duality that has been the story of biotech since the outbreak of the pandemic, said Brennan. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Brennan discusses how CEOs are managing through uncertainty, and why "boring" naked mAbs are the smart move in one field.

View full story: https://www.biocentury.com/article/654451

#biotech #biopharma #pharma #lifescience

00:00 - Introduction
00:59 - State of Play for Biotech
04:34 - How to Choose a CEO Job
18:49 - New Era of Discipline
26:51 - Building a Team